BioLineRx Ltd. has announced a major transaction that will see the company sell a portion of its future royalty payments from APHEXDA (motixafortide) to SCOF Motixafortide Holdings, Inc. This agreement, valued at $5.6 million, is expected to close by November 30, 2026, pending customary closing conditions.

The sale involves BioLineRx transferring 80% of the royalty payments it is entitled to receive under its License Agreement with Ayrmid Pharma Ltd. The agreement allows BioLineRx to retain 20% of the royalties, which translates to a 3.6% royalty on net sales of APHEXDA. This strategic decision is aimed at improving the company’s financial health and funding ongoing research and development activities.

Background

BioLineRx Ltd. operates within the pharmaceutical preparations industry, specifically focusing on developing innovative therapies. The company is traded on the Nasdaq under the ticker symbol BLRX. Its recent filings include a Schedule 13G on November 16, 2026, and several 6-K forms, with the latest being filed on November 18, 2026.

What the Filing Says

According to the recent filing, the Purchase Agreement stipulates that BioLineRx will sell 80% of its future royalty payments, which are based on an 18% royalty rate under the Ayrmid License. The company will receive a one-time payment of $5.6 million, minus the purchaser's documented transaction expenses capped at $100,000. BioLineRx also retains rights to future milestone payments under the Ayrmid License.

Impact

This transaction is likely to impact various stakeholders, including BioLineRx's investors, employees, and the broader pharmaceutical industry. The financial boost from the sale will support ongoing R&D efforts, particularly for the clinical development of GLIX1, a promising therapy in BioLineRx's pipeline. Additionally, the deal may influence competitors in the pharmaceutical preparations sector as they consider similar monetization strategies.

What's Next

The transaction is set to close around November 30, 2026, subject to customary closing conditions. Following the closing, BioLineRx will enter into a Second Amendment to its Loan Agreement with Kreos Capital, which will include a partial loan prepayment of $3.0 million.